AIMS: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan. MATERIALS & METHODS: DNA was isolated from 85 advanced cancer patients treated with 300 or 350 mg/m2 irinotecan and genotyped for haplotype-tag polymorphisms across TOP1, PARP1, TDP1 and XRCC1. Associations between genotypes and haplotypes and log(absolute neutrophil count nadirs) were assessed by linear regression. RESULTS: No associations were observed. CONCLUSION: Our findings suggest that the genes we tested do not influence toxicity of irinotecan when adminstered at 300-350 mg/m2.
AIMS: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancerpatients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan. MATERIALS & METHODS: DNA was isolated from 85 advanced cancerpatients treated with 300 or 350 mg/m2 irinotecan and genotyped for haplotype-tag polymorphisms across TOP1, PARP1, TDP1 and XRCC1. Associations between genotypes and haplotypes and log(absolute neutrophil count nadirs) were assessed by linear regression. RESULTS: No associations were observed. CONCLUSION: Our findings suggest that the genes we tested do not influence toxicity of irinotecan when adminstered at 300-350 mg/m2.
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: Janelle M Hoskins; Eugenio Marcuello; Albert Altes; Sharon Marsh; Taylor Maxwell; Derek J Van Booven; Laia Paré; Robert Culverhouse; Howard L McLeod; Montserrat Baiget Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Kristin L Lockett; M Craig Hall; Jianfeng Xu; S Lilly Zheng; Marianne Berwick; Shu-Chun Chuang; Peter E Clark; Scott D Cramer; Kurt Lohman; Jennifer J Hu Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Luca Paoluzzi; Arun S Singh; Douglas K Price; Romano Danesi; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom Journal: J Clin Pharmacol Date: 2004-08 Impact factor: 3.126
Authors: M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz Journal: Pharmacogenomics J Date: 2016-11-15 Impact factor: 3.550
Authors: Pawadee Lohavanichbutr; Lori C Sakoda; Christopher I Amos; Susanne M Arnold; David C Christiani; Michael P A Davies; John K Field; Eric B Haura; Rayjean J Hung; Takashi Kohno; Maria Teresa Landi; Geoffrey Liu; Yi Liu; Michael W Marcus; Grainne M O'Kane; Matthew B Schabath; Kouya Shiraishi; Stacey A Slone; Adonina Tardón; Ping Yang; Kazushi Yoshida; Ruyang Zhang; Xuchen Zong; Gary E Goodman; Noel S Weiss; Chu Chen Journal: Clin Cancer Res Date: 2017-10-03 Impact factor: 12.531